View ValuationSai Life Sciences 향후 성장Future 기준 점검 3/6Sai Life Sciences (는) 각각 연간 18.8% 및 16.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 18.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 16.3% 로 예상됩니다.핵심 정보18.8%이익 성장률18.55%EPS 성장률Life Sciences 이익 성장23.9%매출 성장률16.8%향후 자기자본이익률16.31%애널리스트 커버리지Good마지막 업데이트22 Jul 2026최근 향후 성장 업데이트Price Target Changed • May 20Price target increased by 8.0% to ₹1,275Up from ₹1,181, the current price target is an average from 6 analysts. New target price is 12% above last closing price of ₹1,141. Stock is up 54% over the past year. The company is forecast to post earnings per share of ₹19.35 for next year compared to ₹16.63 last year.모든 업데이트 보기Recent updates공고 • Jul 01Sai Life Sciences Limited to Report Q1, 2027 Results on Aug 06, 2026Sai Life Sciences Limited announced that they will report Q1, 2027 results on Aug 06, 2026Price Target Changed • May 20Price target increased by 8.0% to ₹1,275Up from ₹1,181, the current price target is an average from 6 analysts. New target price is 12% above last closing price of ₹1,141. Stock is up 54% over the past year. The company is forecast to post earnings per share of ₹19.35 for next year compared to ₹16.63 last year.Reported Earnings • May 16Full year 2026 earnings: EPS and revenues miss analyst expectationsFull year 2026 results: EPS: ₹16.63 (up from ₹8.83 in FY 2025). Revenue: ₹22.4b (up 32% from FY 2025). Net income: ₹3.49b (up 105% from FY 2025). Profit margin: 16% (up from 10.0% in FY 2025). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) also missed analyst estimates by 3.0%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.공고 • Apr 21Sai Life Sciences Limited to Report Q4, 2026 Results on May 14, 2026Sai Life Sciences Limited announced that they will report Q4, 2026 results at 4:00 PM, Indian Standard Time on May 14, 2026Buy Or Sell Opportunity • Feb 12Now 20% undervaluedOver the last 90 days, the stock has risen 6.7% to ₹930. The fair value is estimated to be ₹1,167, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 69%. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 51% in the next 2 years.Reported Earnings • Feb 06Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: ₹4.77 (up from ₹2.89 in 3Q 2025). Revenue: ₹5.65b (up 28% from 3Q 2025). Net income: ₹1.00b (up 86% from 3Q 2025). Profit margin: 18% (up from 12% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.공고 • Jan 22Sai Life Sciences Limited to Report Q3, 2026 Results on Feb 05, 2026Sai Life Sciences Limited announced that they will report Q3, 2026 results on Feb 05, 2026Reported Earnings • Nov 07Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: EPS: ₹4.01 (up from ₹2.22 in 2Q 2025). Revenue: ₹5.53b (up 36% from 2Q 2025). Net income: ₹838.4m (up 102% from 2Q 2025). Profit margin: 15% (up from 10% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 8.2%. Earnings per share (EPS) also surpassed analyst estimates by 40%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.공고 • Oct 24Sai Life Sciences Limited to Report Q2, 2026 Results on Nov 06, 2025Sai Life Sciences Limited announced that they will report Q2, 2026 results at 4:00 PM, Indian Standard Time on Nov 06, 2025공고 • Aug 08Sai Life Sciences Limited, Annual General Meeting, Sep 11, 2025Sai Life Sciences Limited, Annual General Meeting, Sep 11, 2025, at 10:30 Indian Standard Time.Reported Earnings • Aug 08First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: EPS: ₹2.90 (up from ₹0.75 in 1Q 2025). Revenue: ₹5.06b (up 50% from 1Q 2025). Net income: ₹604.6m (up 332% from 1Q 2025). Profit margin: 12% (up from 4.1% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 38%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.공고 • Jul 21Sai Life Sciences Limited to Report Q1, 2026 Results on Aug 07, 2025Sai Life Sciences Limited announced that they will report Q1, 2026 results on Aug 07, 2025공고 • Jun 20TPG Reportedly to Sell 6% Stake in Sai Life Sciences at Estimated Price of $102 Million in Block DealTPG Inc. (NasdaqGS:TPG) is likely to sell 12.5 million shares representing 6% stake Sai Life Sciences Limited (NSEI:SAILIFE) at an estimated deal size of $102 million, according to a report. The base price of the deal is likely at INR 710 per share which is a discount of 2.5% over the current market price. There will be a 60-day lock-in period for the seller, a CNBC-TV18 report said, citing sources. TPG held over 51.5 million equity shares in the company as on March 31, 2025 through TPG Asia VII SF PTE Ltd, which accounts for a 24.73% stake in this smallcap company. The market capitalisation of the company is at INR 152,300 million.Reported Earnings • May 14Full year 2025 earnings released: EPS: ₹8.83 (vs ₹4.57 in FY 2024)Full year 2025 results: EPS: ₹8.83 (up from ₹4.57 in FY 2024). Revenue: ₹17.3b (up 18% from FY 2024). Net income: ₹1.70b (up 106% from FY 2024). Profit margin: 9.8% (up from 5.7% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India.Board Change • May 08Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Ramesh Iyer was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Apr 23Sai Life Sciences Limited Announces Change of Designation of Sauri Gudlavalleti to Head of Special Projects from Chief Operating Officer, Effective April 23, 2025Sai Life Sciences Limited announced that Mr. Sauri Gudlavalleti, who held the position of Chief Operating Officer, will move into the new role of Head of Special Projects with effect from the close of business on 23 April, 2025. The change in role of Mr. Sauri Gudlavalleti is pursuant his request received in this regard due to his personal commitments. He Ceased to be a part of senior management with effect from 23rd April, 2025.공고 • Mar 25Sai Life Sciences Limited Announces Cessation of Rajagopal Srirama Tatta as Independent DirectorSai Life Sciences Limited announced cessation of Mr. Rajagopal Srirama Tatta as Independent Director of the Company with effect from the closing of Business hours on 25 March 2025, consequent to the end of his term as an Independent Director.Recent Insider Transactions • Feb 27Insider recently sold ₹51m worth of stockOn the 21st of February, Tuneer Ghosh sold around 71k shares on-market at roughly ₹713 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹109m. Insiders have been net sellers, collectively disposing of ₹830m more than they bought in the last 12 months.Reported Earnings • Feb 07Third quarter 2025 earnings releasedThird quarter 2025 results: EPS: ₹2.89. Net income: ₹538.5m (up ₹538.5m from 3Q 2024). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.공고 • Jan 25Sai Life Sciences Limited to Report Q3, 2025 Results on Feb 06, 2025Sai Life Sciences Limited announced that they will report Q3, 2025 results on Feb 06, 2025이익 및 매출 성장 예측BSE:544306 - 애널리스트 향후 추정치 및 과거 재무 데이터 (INR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수3/31/202937,3726,1073,2687,24233/31/202832,5005,1938216,10063/31/202726,4554,111-5,9744,75563/31/202621,9253,489-8385,091N/A12/31/202521,6993,329N/AN/AN/A9/30/202520,5322,864-1,9783,055N/A6/30/202519,1132,441N/AN/AN/A3/31/202516,9461,701-5523,140N/A12/31/202415,5431,380N/AN/AN/A9/30/202414,9811,2371532,433N/A6/30/202414,237758N/AN/AN/A3/31/202414,6528288142,631N/A3/31/202312,1711001,0632,194N/A3/31/20228,69662-1,0201,049N/A3/31/20217,599611-2,985-364N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 544306 의 연간 예상 수익 증가율(18.8%)이 saving rate(6.9%)보다 높습니다.수익 vs 시장: 544306 의 연간 수익(18.8%)이 Indian 시장(16.3%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: 544306 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 544306 의 수익(연간 16.8%)이 Indian 시장(연간 11.1%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 544306 의 수익(연간 16.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 544306의 자본 수익률은 3년 후 16.3%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/23 20:51종가2026/07/23 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Sai Life Sciences Limited는 9명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Mehul ShethHDFC Securities LimitedRahul JeewaniIIFL ResearchAlok DalalJefferies LLC6명의 분석가 더 보기
Price Target Changed • May 20Price target increased by 8.0% to ₹1,275Up from ₹1,181, the current price target is an average from 6 analysts. New target price is 12% above last closing price of ₹1,141. Stock is up 54% over the past year. The company is forecast to post earnings per share of ₹19.35 for next year compared to ₹16.63 last year.
공고 • Jul 01Sai Life Sciences Limited to Report Q1, 2027 Results on Aug 06, 2026Sai Life Sciences Limited announced that they will report Q1, 2027 results on Aug 06, 2026
Price Target Changed • May 20Price target increased by 8.0% to ₹1,275Up from ₹1,181, the current price target is an average from 6 analysts. New target price is 12% above last closing price of ₹1,141. Stock is up 54% over the past year. The company is forecast to post earnings per share of ₹19.35 for next year compared to ₹16.63 last year.
Reported Earnings • May 16Full year 2026 earnings: EPS and revenues miss analyst expectationsFull year 2026 results: EPS: ₹16.63 (up from ₹8.83 in FY 2025). Revenue: ₹22.4b (up 32% from FY 2025). Net income: ₹3.49b (up 105% from FY 2025). Profit margin: 16% (up from 10.0% in FY 2025). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) also missed analyst estimates by 3.0%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.
공고 • Apr 21Sai Life Sciences Limited to Report Q4, 2026 Results on May 14, 2026Sai Life Sciences Limited announced that they will report Q4, 2026 results at 4:00 PM, Indian Standard Time on May 14, 2026
Buy Or Sell Opportunity • Feb 12Now 20% undervaluedOver the last 90 days, the stock has risen 6.7% to ₹930. The fair value is estimated to be ₹1,167, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 69%. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 51% in the next 2 years.
Reported Earnings • Feb 06Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: ₹4.77 (up from ₹2.89 in 3Q 2025). Revenue: ₹5.65b (up 28% from 3Q 2025). Net income: ₹1.00b (up 86% from 3Q 2025). Profit margin: 18% (up from 12% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.
공고 • Jan 22Sai Life Sciences Limited to Report Q3, 2026 Results on Feb 05, 2026Sai Life Sciences Limited announced that they will report Q3, 2026 results on Feb 05, 2026
Reported Earnings • Nov 07Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: EPS: ₹4.01 (up from ₹2.22 in 2Q 2025). Revenue: ₹5.53b (up 36% from 2Q 2025). Net income: ₹838.4m (up 102% from 2Q 2025). Profit margin: 15% (up from 10% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 8.2%. Earnings per share (EPS) also surpassed analyst estimates by 40%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.
공고 • Oct 24Sai Life Sciences Limited to Report Q2, 2026 Results on Nov 06, 2025Sai Life Sciences Limited announced that they will report Q2, 2026 results at 4:00 PM, Indian Standard Time on Nov 06, 2025
공고 • Aug 08Sai Life Sciences Limited, Annual General Meeting, Sep 11, 2025Sai Life Sciences Limited, Annual General Meeting, Sep 11, 2025, at 10:30 Indian Standard Time.
Reported Earnings • Aug 08First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: EPS: ₹2.90 (up from ₹0.75 in 1Q 2025). Revenue: ₹5.06b (up 50% from 1Q 2025). Net income: ₹604.6m (up 332% from 1Q 2025). Profit margin: 12% (up from 4.1% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 38%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.
공고 • Jul 21Sai Life Sciences Limited to Report Q1, 2026 Results on Aug 07, 2025Sai Life Sciences Limited announced that they will report Q1, 2026 results on Aug 07, 2025
공고 • Jun 20TPG Reportedly to Sell 6% Stake in Sai Life Sciences at Estimated Price of $102 Million in Block DealTPG Inc. (NasdaqGS:TPG) is likely to sell 12.5 million shares representing 6% stake Sai Life Sciences Limited (NSEI:SAILIFE) at an estimated deal size of $102 million, according to a report. The base price of the deal is likely at INR 710 per share which is a discount of 2.5% over the current market price. There will be a 60-day lock-in period for the seller, a CNBC-TV18 report said, citing sources. TPG held over 51.5 million equity shares in the company as on March 31, 2025 through TPG Asia VII SF PTE Ltd, which accounts for a 24.73% stake in this smallcap company. The market capitalisation of the company is at INR 152,300 million.
Reported Earnings • May 14Full year 2025 earnings released: EPS: ₹8.83 (vs ₹4.57 in FY 2024)Full year 2025 results: EPS: ₹8.83 (up from ₹4.57 in FY 2024). Revenue: ₹17.3b (up 18% from FY 2024). Net income: ₹1.70b (up 106% from FY 2024). Profit margin: 9.8% (up from 5.7% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India.
Board Change • May 08Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Ramesh Iyer was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Apr 23Sai Life Sciences Limited Announces Change of Designation of Sauri Gudlavalleti to Head of Special Projects from Chief Operating Officer, Effective April 23, 2025Sai Life Sciences Limited announced that Mr. Sauri Gudlavalleti, who held the position of Chief Operating Officer, will move into the new role of Head of Special Projects with effect from the close of business on 23 April, 2025. The change in role of Mr. Sauri Gudlavalleti is pursuant his request received in this regard due to his personal commitments. He Ceased to be a part of senior management with effect from 23rd April, 2025.
공고 • Mar 25Sai Life Sciences Limited Announces Cessation of Rajagopal Srirama Tatta as Independent DirectorSai Life Sciences Limited announced cessation of Mr. Rajagopal Srirama Tatta as Independent Director of the Company with effect from the closing of Business hours on 25 March 2025, consequent to the end of his term as an Independent Director.
Recent Insider Transactions • Feb 27Insider recently sold ₹51m worth of stockOn the 21st of February, Tuneer Ghosh sold around 71k shares on-market at roughly ₹713 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹109m. Insiders have been net sellers, collectively disposing of ₹830m more than they bought in the last 12 months.
Reported Earnings • Feb 07Third quarter 2025 earnings releasedThird quarter 2025 results: EPS: ₹2.89. Net income: ₹538.5m (up ₹538.5m from 3Q 2024). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.
공고 • Jan 25Sai Life Sciences Limited to Report Q3, 2025 Results on Feb 06, 2025Sai Life Sciences Limited announced that they will report Q3, 2025 results on Feb 06, 2025